GLP-1 Drugs, Libido, and Testosterone in Men: What's Well Documented, and What's Speculation?

Among the promises accompanying the popularity of GLP-1 drugs (semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) is one concerning libido and testosterone in men — sometimes presented as a direct drug effect, sometimes as a natural consequence of weight loss. This distinction matters, because the two mechanisms have very different strengths of evidence in the scientific literature.

On one hand, there's a well-established, long-standing body of knowledge about the link between obesity and lower testosterone in men — a relationship known in endocrinology literature long before GLP-1 drugs existed, described more fully in our entries on testosterone and on SHBG. On the other hand, there are newer, smaller studies suggesting GLP-1 drugs themselves might have some direct effect on the hormonal axis, independent of weight loss itself — but the evidence for this specific mechanism is considerably thinner.

The link between excess fat tissue and lower testosterone in men rests on several overlapping mechanisms, well described in the endocrinology literature. Fat tissue, especially visceral fat, is a site of activity for the enzyme aromatase, which converts testosterone into estradiol — more fat tissue means more of this conversion, and higher estradiol in turn suppresses LH secretion through negative feedback at the hypothalamic and pituitary level, limiting further testosterone production in the testes. Additionally, obesity and the insulin resistance that accompanies it lower SHBG (sex hormone-binding globulin) — a transport protein, described more fully in our SHBG entry, that normally stabilizes and partly determines the amount of biologically available testosterone.

This mechanism means that weight reduction — regardless of method, whether diet, exercise, bariatric surgery, or a GLP-1 drug — should theoretically lead to a partial reversal of this process: less fat tissue, less aromatase activity, higher SHBG, and consequently higher total and free testosterone. This isn't a speculation specific to GLP-1 drugs — it's a general principle confirmed in studies of weight loss by any method in men with obesity.

Evidence directly evaluating GLP-1 drugs' effect on testosterone and sexual function in men is much scarcer than general studies on weight and testosterone, and available studies are smaller and cover specific populations — mainly men with obesity and coexisting functional hypogonadism (a condition in which low testosterone results from obesity itself, not from a primary disorder of the testes or pituitary).

Newer systematic reviews evaluating GLP-1 and male reproductive health (covering semaglutide and other drugs in this class) consistently describe a rise in total testosterone mainly in populations with obesity, type 2 diabetes, or functional hypogonadism — not in healthy, normally nourished men with baseline-normal hormone levels, in whom these drugs don't show a significant effect on the hormonal axis. This further supports the conclusion that the effect is largely mediated through weight reduction and metabolic improvement, not through some universal, direct hormonal mechanism of the drug.

This distinction has practical significance: if the mechanism is largely indirect, then weight reduction by any effective method in a man with obesity should produce a similar rise in testosterone and improvement in libido, not only a specific GLP-1 drug — which is in fact confirmed by the previously cited dietary trial by Moran et al., unrelated to any drug.

The link between GLP-1 drugs and testosterone and libido in men is real, but largely indirect — a consequence of weight reduction and the reversal of obesity's hormonal effects, not a separate, magical mechanism of the drug itself. This is an important distinction, because it means the benefit is likely proportional to the scale of fat loss and the baseline degree of obesity-related hypogonadism, not a universal property of this drug class for every man.